申克孢子丝菌毒力因子及宿主抗感染免疫的研究进展

中国真菌学杂志　 2013, Vol. 8 　Issue (5): 307-310.

申克孢子丝菌毒力因子及宿主抗感染免疫的研究进展

万雪, 贺丹, 王丽

吉林大学基础医学院病原生物学系吉林大学真菌研究中心人兽共患病研究教育部重点实验室, 长春 130021

收稿日期:2013-07-30 出版日期:2013-10-28 发布日期:2013-10-28
通讯作者: 王丽,E-mail:wli99@jlu.edu.cn E-mail:wli99@jlu.edu.cn
作者简介:万雪,女 (汉族),硕士研究生在读.E-mail:wanxue11@mails.jlu.edu.cn
基金资助:
国家自然科学基金重大国际合作项目(30910103903)

Virulence factors and the host immune responses of Sporothrix schenckii

WAN Xue, HE Dan, WANG Li

Department of Pathogenobiology, College of Basic Medical Sciences, Jilin University, Jilin University Research Center (JUMRC), Key Laboratory of Zoonosis Research, Ministry of Education, Changchun 130021, China

Received:2013-07-30 Online:2013-10-28 Published:2013-10-28

摘要/Abstract

摘要： 申克孢子丝菌是一种重要的双相型真菌,其引起的孢子丝菌病是一种常见的侵袭性皮肤感染。研究该菌毒力因子及宿主对其抗感染免疫对于深入了解其致病性及防治该病具有重要意义。该文介绍了申克孢子丝菌毒力因子及宿主对其抗感染免疫方面的研究进展。

关键词: 申克孢子丝菌, 孢子丝菌病, 毒力因子, 抗感染免疫

Abstract: Sporothrix schenckii is an important dimorphic fungi and it can cause Sporotrichosis which is a common invasive skin infection. A further understanding for the characterization of virulence factors and the host immune responses of this fungus should be done. It is very importantand significant for the study on their pathogenicity,prevention and treatment of this disease. Here we review briefly the advancement on the characterization of virulence factors and the host immune responses of Sporothrix schenckii.

Key words: Sporothrix schenckii, Sporotrichosis, virulence factors, immune responses

中图分类号:

R379.9

万雪, 贺丹, 王丽. 申克孢子丝菌毒力因子及宿主抗感染免疫的研究进展[J]. 中国真菌学杂志, 2013, 8(5): 307-310.

WAN Xue, HE Dan, WANG Li. Virulence factors and the host immune responses of Sporothrix schenckii[J]. Chinese Journal of Mycology, 2013, 8(5): 307-310.

参考文献

[1] Hektoen L, Perkins CF. Refractory subcutaneous abscesses caused by Sporothrix schenckii. A new pathogenic fungus[J]. The Journal of experimental medicine, 1900, 5(1): 77-89.
[2] Dixon DM, Salkin IF, Duncan RA, et al. Isolation and characterization of Sporothrix schenckii from clinical and environmental sources associated with the largest US epidemic of sporotrichosis[J]. Journal of clinical microbiology, 1991, 29(6): 1106-1113.
[3] Neyra E, Fonteyne PA, Swinne D, et al. Epidemiology of human sporotrichosis investigated by amplified fragment length polymorphism[J]. Journal of clinical microbiology, 2005, 43(3): 1348-1352.
[4] Cruz LCH. Sporothrix schenckii complex. Review of the literature and considerations on the diagnosis and epidemiology[J]. Veterinária e Zootecnia, 2013, 20(Special edition): 8-28.
[5] Zhang Z, Hou B, Xin Y, et al. Protein profiling of the dimorphic pathogenic fungus, Sporothrix schenckii[J]. Mycopathologia, 2012, 173(1): 1-11.
[6] Lima OC, Figueiredo CC, Pereira BAS, et al. Adhesion of the human pathogen Sporothrix schenckii to several extracellular matrix proteins[J]. Brazilian journal of medical and biological research, 1999, 32(5): 651-657.
[7] Lima OC, Figueiredo CC, Previato JO, et al. Involvement of fungal cell wall components in adhesion of Sporothrix schenckii to human fibronectin[J]. Infection and immunity, 2001, 69(11): 6874-6880.
[8] Teixeira PAC, de Castro RA, Nascimento RC, et al. Cell surface expression of adhesins for fibronectin correlates with virulence in Sporothrix schenckii[J]. Microbiology, 2009, 155(11): 3730-3738.
[9] Lima OC, Bouchara JP, Renier G, et al. Immunofluorescence and flow cytometry analysis of fibronectin and laminin binding to Sporothrix schenckii yeast cells and conidia[J]. Microbial pathogenesis, 2004, 37(3): 131-140.
[10] Ruíz-Cendoya M, Rodriguez M, Mariné M, et al. In vitro interactions of itraconazole and micafungin against clinically important filamentous fungi[J]. International journal of antimicrobial agents, 2008, 32(5): 418-420.
[11] Jacobson ES. Pathogenic roles for fungal melanins[J]. Clinical Microbiology Reviews, 2000, 13(4): 708-717.
[12] Romero-Martinez R, Wheeler M, Guerrero-Plata A, et al. Biosynthesis and Functions of Melanin in Sporothrix schenckii[J]. Infection and immunity, 2000, 68(6): 3696-3703.
[13] Almeida-Paes R, Frases S, Fialho Monteiro PC, et al. Growth conditions influence melanization of Brazilian clinical Sporothrix schenckii isolates[J]. Microbes and Infection, 2009, 11(5): 554-562.
[14] Morris-Jones R, Youngchim S, Gomez BL, et al. Synthesis of melanin-like pigments by Sporothrix schenckii in vitro and during mammalian infection[J]. Infection and immunity, 2003, 71(7): 4026-4033.
[15] Casadevall A. Cards of virulence and the global virulome for humans[J]. MICROBE-AMERICAN SOCIETY FOR MICROBIOLOGY, 2006, 1(8): 359.
[16] Kwon-Chung KJ, Bennett JE. Medical Mycology[M]. 2nd ed. Pennsylvania: Lea & Febiger, 1992.
[17] Mesa-Arango AC, del Rocío Reyes-Montes M, Pérez-Mejía A, et al. Phenotyping and genotyping of Sporothrix schenckii isolates according to geographic origin and clinical form of sporotrichosis[J]. Journal of clinical microbiology, 2002, 40(8): 3004-3011.
[18] Carlos IZ, Sassá MF, da Graņa Sgarbi DB, et al. Current research on the immune response to experimental sporotrichosis[J]. Mycopathologia, 2009, 168(1): 1-10.
[19] da Graņa Sgarbi DB, da Silva AJR, Carlos IZ, et al. Isolation of ergosterol peroxide and its reversion to ergosterol in the pathogenic fungus Sporothrix schenckii[J]. Mycopathologia, 1997, 139(1): 9-14.
[20] Scott EN, Muchmore HG, Fine DP. Activation of the alternative complement pathway by Sporothrix schenckii[J]. Infection and immunity, 1986, 51(1): 6-9.
[21] Torinuki W, Tagami H. Complement activation by Sporothrix schenckii[J]. Archives of dermatological research, 1985, 277(4): 332-333.
[22] Tachibana T, Matsuyama T, Mitsuyama M. Involvement of CD4⁺ T cells and macrophages in acquired protection against infection with Sporothrix schenckii in mice[J]. Medical Mycology, 1999, 37(6): 397-404.
[23] Carlos IZ, Sgarbi DBG, Santos GC, et al. Sporothrix schenckii Lipid Inhibits Macrophage Phagocytosis: Involvement of Nitric Oxide and Tumour Necrosis Factor-α[J]. Scandinavian journal of immunology, 2003, 57(3): 214-220.
[24] Carlos IZ, Zini MMC, da Graņa Sgarbi DB, et al. Disturbances in the production of inteleukin-1 tumor and necrosis factor in disseminated murine sporotrichosis[J]. Mycopathologia, 1994, 127(3): 189-194.
[25] Maia DCG, Sassá MF, Placeres MCP, et al. Influence of Th1/Th2 cytokines and nitric oxide in murine systemic infection induced by Sporothrix schenckii[J]. Mycopathologia, 2006, 161(1): 11-19.
[26] Nascimento RC, Espindola NM, Castro RA, et al. Passive immunization with monoclonal antibody against a 70‐kDa putative adhesin of Sporothrix schenckii induces protection in murine sporotrichosis[J]. European journal of immunology, 2008, 38(11): 3080-3089.
[27] Nascimento RC, Almeida SR. Humoral immune response against soluble and fractionate antigens in experimental sporotrichosis[J]. FEMS Immunology & Medical Microbiology, 2005, 43(2): 241-247.
[28] Almeida-Paes R, Pimenta MA, Monteiro PCF, et al. Immunoglobulins G, M, and A against Sporothrix schenckii exoantigens in patients with sporotrichosis before and during treatment with itraconazole[J]. Clinical and Vaccine Immunology, 2007, 14(9): 1149-1157.
[29] Valle-Aviles L, Valentin-Berrios S, Gonzalez-Mendez RR, et al. Functional, genetic and bioinformatic characterization of a calcium/calmodulin kinase gene in Sporothrix schenckii[J]. BMC microbiology, 2007, 7(1): 107.
[30] Sassá MF, Saturi AET, Souza LF, et al. Response of macrophage Toll‐like receptor 4 to a Sporothrix schenckii lipid extract during experimental sporotrichosis[J]. Immunology, 2009, 128(2): 301-309.